The Saudi National Policy and Protocol for Epidermolysis Bullosa

This protocol's objective is to offer evidence-based suggestions for the identification, treatment, and management of epidermolysis bullosa (EB) in Saudi Arabia. EB is a rare genetic condition that results in blistering and skin fragility. Depending on the subtype, it can produce a variety of consequences. The four primary kinds of EB are EB Simplex, Junctional EB, Dystrophic EB, and Kindler EB. This guideline provides a thorough understanding of EB and describes diagnostic techniques including genetic testing and immunofluorescence mapping. The significance of an interdisciplinary team (IDT) approach in treating severe instances is also covered, guaranteeing integrated treatment across wound care, nutrition, dermatology, genetics, and psychosocial support. In addition, the guideline discusses the role of new treatments for EB, such as Beremagene geperpavec (B-VEC), and stresses the necessity of creating a National Saudi EB Registry to maximize patient care and guarantee fair access to treatment. The guideline also emphasizes the importance of genetic counseling for prenatal diagnosis, family planning, and parental screening, as well as the need to address the psychological difficulties that people living with EB and their families face. In summary, this guideline offers a structured framework for physicians and healthcare providers to guarantee the best possible care for people living with EB in Saudi Arabia, with the goal of improving clinical outcomes, quality of life, and long-term management of the disease.